Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.

Cell communication and signaling : CCS - 28 Oct 2019

Ito Masaoki, Codony-Servat Carles, Codony-Servat Jordi, Lligé David, Chaib Imane, Sun Xiaoyan, Miao Jing, Sun Rongwei, Cai Xueting, Verlicchi Alberto, Okada Morihito, Molina-Vila Miguel Angel, Karachaliou Niki, Cao Peng, Rosell Rafael

Abstract excerpt

INTRODUCTION: p21-activated kinase 1 (PAK1) stimulates growth and metastasis in non-small cell lung cancer (NSCLC). Protein kinase C iota (PKCι) is an enzyme highly expressed in NSCLC, regulating PAK1 signaling. In the present study we explored whether the PKCι-PAK1 signaling pathway approach can be an efficient target in different types of NSCLC cell and mouse models. METHODS: The effect of IPA-3 (PAK1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Isoenzymes

Share to Molecular Targeted Therapy

Share to p21-Activated Kinases

Share to Protein Kinase C

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 31660987
DOI: 10.1186/s12964-019-0446-z
PMCID: PMC6819333

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.PMID 31660987Read ↗

Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.Semantic proximity Read ↗

Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC.Semantic proximity Read ↗

PAK1 as a Potential Therapeutic Target in Male Smokers with EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

The PI3k inhibitors: new hopes in the battle against advanced NSCLC.Semantic proximity Read ↗

Therapeutic Potential of Targeting PAK SignalingSemantic proximity Read ↗

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.Semantic proximity Read ↗

PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.Semantic proximity Read ↗

Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.Semantic proximity Read ↗

PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.Semantic proximity Read ↗

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer.Semantic proximity Read ↗

A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.Semantic proximity Read ↗

PKCι maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.